Finerenone is associated with pronounced uric acid reduction in hyperuricemic diabetic kidney disease: a real-world analysis
BackgroundDiabetic kidney disease (DKD) is a critical complication of type 2 diabetes, often compounded by hyperuricemia, which may accelerate renal function decline. While finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), provides renal and cardiovascular benefits, its impact...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2026-03-01
|
| Serie: | Frontiers in Pharmacology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1782658/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|